Rackoff W R, Manno C S
Section of Pediatric Hematology-Oncology, James Whitcomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis 46202-5225.
Am J Pediatr Hematol Oncol. 1994 May;16(2):156-9.
We report that the use of alternate-day cyclosporine and prednisone improved the clinical course of a 6-year-old child with severe Evans syndrome. Before the use of cyclosporine the child had experienced life-threatening episodes of hemolytic anemia despite the use of multiple therapeutic modalities.
Cyclosporine was given at a dose of 10 mg/kg/day divided into two doses on alternate days.
The use of cyclosporine resulted in increased hemoglobin levels, increased platelet counts, and the reduction of the patient's prednisone dose from 2 mg/kg/day to as low as 1 mg/kg every other day. With this regimen, the patient had less severe hemolytic anemia, was less thrombocytopenic, and had fewer hospitalizations. No major toxic effects were associated with cyclosporine therapy.
The regimen of alternate-day cyclosporine and prednisone may prove to be useful in the treatment of other patients with refractory Evans syndrome.
